The systemic treatment of malignant pleural mesothelioma (MPM) in routine practice has remained unchanged since 2003, with almost a decade passing since any new treatment being approved for this disease. However, there are currently more novel agents in clinical trials than ever before, bringing hope that the next decade will see improvements in survival and other patient outcomes. This review will focus on systemic treatments for advanced disease, with an overview of current practice and a view to the future of chemotherapy and targeted therapies in mesothelioma. The use of chemotherapy as part of multimodality treatment for mesothelioma is covered in a companion paper in this issue and will not be addressed here.

First-line chemotherapy

Despite decades of clinical research, cytotoxic chemotherapy remains one of the few therapeutic options that has been proven to improve survival in patients with MPM in a randomised controlled trial (Figure 1). Readers will be familiar with the pivotal ‘Emphacis’ trial which demonstrated that the combination of cisplatin and pemetrexed gave a three month survival benefit over cisplatin alone, improving median survival from 9.3 to 12.1 months (P=0.02) in patients with advanced disease (1). This modest survival increase was also associated with improvements in quality of life (2). A similar survival benefit was seen with the addition of raltitrexed to cisplatin, with survival increasing from 8.8 to 11.4 months, although objective radiological response rates were lower to this combination than to cisplatin and pemetrexed (3). Whilst neither of these trials included a comparator arm of Best Supportive Care, the British MS01 study did randomise patients to active symptom control (ASC) with or without either vinorelbine or MVP (mitomycin C, vinblastine, and cisplatin) (4). This trial accrued poorly, and after closing early, both chemotherapy arms were combined for analysis of the primary endpoint; no survival benefit was seen overall for the combined chemotherapy arms as compared with ASC (HR 0.89; P=0.29). Nevertheless, when the two arms were analysed independently, there was a substantial difference between them with a two month survival benefit for vinorelbine over ASC nearing statistical significance (HR 0.80, P=0.08), whilst MVP did not give a signal for benefit (HR 0.99, P=0.95). Although no trial has demonstrated a benefit of platinum and an antifolate over supportive care, the weight of the evidence suggests that an active platinum-based combination is likely to give a benefit of at least three months over best supportive care.

On the basis of these data, the combination of cisplatin and pemetrexed has become standard first-line therapy worldwide for patients who are not suitable for aggressive surgery, or in whom chemotherapy is recommended as part of a multimodality regimen. Carboplatin is often substituted for cisplatin, due to simpler and shorter administration and a perception of lesser toxicity. Although carboplatin use is not supported by randomised evidence, and there has been no direct comparison between the two platinum agents, phase I and II studies have demonstrated similar activity of either carboplatin or cisplatin with pemetrexed, with objective radiological response rates between 20% and 30% (5,6). Most importantly, although an expanded access program showed a slightly lower response rate for carboplatin based
therapy, one year survival and time to progression were very similar (7). Most oncologists will substitute carboplatin for cisplatin on the basis of clinical judgement, for example where patients have medical contraindications to cisplatin.

Despite the use of cisplatin or carboplatin with pemetrexed as first-line therapy for advanced mesothelioma for nearly 10 years, many practical questions remain in our use of chemotherapy in mesothelioma. Some of these uncertainties have been answered in non-small cell lung cancer (NSCLC), and whilst the numbers of patients with mesothelioma would be sufficient for international trial efforts to answer these questions, they have not been (and may never be) a high priority over novel treatment trials. In one example, treatment of non-small cell lung cancer has recently moved to incorporate a maintenance phase following primary chemotherapy, a strategy which has been supported by a number of randomised clinical trials and meta-analyses (8-11). In mesothelioma, appropriate randomised studies have not yet been done, although a small study has demonstrated the safety and feasibility of continuing single agent pemetrexed (12). A phase II trial randomising patients to continue single agent pemetrexed or observation only is underway (NCT01085630) but is not likely to report for another two years. Similarly, it will probably remain unclear whether 4 cycles of chemotherapy provides similar survival benefits with lesser toxicity than 6 cycles or ongoing chemotherapy, as shown in NSCLC (13).

Finally, in asymptomatic patients who would be suitable for cytotoxic chemotherapy and will not be having surgical management, should we start chemotherapy immediately on diagnosis, or delay treatment until the development of symptoms and measurable disease? One small randomised trial of 43 patients using the inactive MVP regimen suggested a survival benefit for immediate treatment, however the lack of activity of MVP when compared with Active Symptom Control makes this result unconvincing (14), and the question remains unanswered.

If we recommend platinum and pemetrexed chemotherapy, how can we best select our patients and predict for response to therapy? In non-small cell lung cancer, tumor histology is an important determinant of response, with squamous cell carcinoma being highly resistant to pemetrexed (15). Pemetrexed is a multitargeted antifolate agent, inhibiting thymidylate synthetase (TS), dihydrofolate reductase (DHFR), and glycaminide ribonucleotide formyltransferase (GARFT). Resistance to pemetrexed in squamous cell carcinoma appears to be mediated by high levels of TS present in this histological subtype. There is some indication that this may be relevant for mesothelioma, with a small study finding a significant correlation between low TS protein expression on immunohistochemistry and time to progression (TTP) and overall survival (OS) in patients treated with pemetrexed, which was not seen in untreated patients (16). However, this finding is unconfirmed and should not be used to guide management in individual patients. Although sarcomatoid histology, found in approximately 10% of patients, has invariably been found to predict poor prognosis, neither randomised trials showing survival benefits for combination chemotherapy reported on an interaction between efficacy and tumor subtype (1,3). The cytotoxicity of cisplatin and carboplatin is mediated through platinum-DNA adult formation, which can be repaired by excision repair cross-complementing 1 (ERCCI) and other enzymes in the nucleotide excision

Figure 1 axial computed tomography scan showing pre-treatment disease (A) and a partial response to chemotherapy with cisplatin and pemetrexed (B) after four cycles of treatment
repair pathway. Although low levels of ERCC1 predict for potential benefit from platinum-based therapy in NSCLC, this relationship has not been borne out in mesothelioma, with high ERCC1 protein expression appearing to predict for survival benefit, irrespective of treatment (16). Finally, the alpha folate receptor is over-expressed by most mesotheliomas, but did not appear to correlate with response to pemetrexed in vitro and is not known to be useful in patient selection (17,18).

Other prognostic indicators which do not yet appear to have a role in predicting response to systemic therapy include serum mesothelin levels, 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) at baseline, and molecular tests. Serum mesothelin levels reflect disease burden and predict survival, also decreasing with response to treatment and increasing with disease progression. However, there is no indication that elevated mesothelin levels are predictive of treatment response (19). Quantitative baseline FDG-PET parameters, notably total glycolytic volume (TGV) and to a lesser extent maximum standardised uptake value (SUVmax), are also prognostic indicators, at least in those with non-sarcomatoid disease (20). However, again, baseline FDG-PET parameters do not appear predictive of treatment response. A four-gene expression ratio test performed better than histological subtype, tumor stage, and lymph node status as a predictor of surgical outcomes, but has not been reported as a predictor of outcomes on systemic therapy (21).

**Second-line chemotherapy**

After initial chemotherapy, or aggressive multimodality therapy, patients almost invariably experience disease recurrence or progression. Many patients will be fit for, and may want, second-line chemotherapy at this point. The only randomised clinical trial in this setting showing an improvement in progression free survival (PFS) was undertaken before the widespread use of pemetrexed as first-line treatment. This study compared second-line pemetrexed versus best supportive care, with a significantly higher rate of partial response, disease control, and longer PFS in the group receiving pemetrexed (22). However, there is no randomised trial testing the use of pemetrexed as re-treatment following previous first-line use. Nevertheless, a recent retrospective review of second-line chemotherapy found that disease control with second-line therapy was better in those patients who received pemetrexed, and those with a prolonged time to progression (≥12 months) after first-line therapy (23). Furthermore, patients re-treated with a platinum-pemetrexed combination had a lower risk of death than those treated with pemetrexed alone (HR = 0.11, P<0.001), although this observation may be confounded by selection bias in this non-randomised comparison, with fitter patients potentially more likely to receive combination therapy. Together, this suggests that re-treatment with pemetrexed and a platinum is a reasonable option for second-line therapy in fit patients with previous disease control after pemetrexed-based treatment.

A variety of cytotoxic agents have some activity in second-line treatment, but none have had the appropriate randomised controlled design to satisfy regulators or clinicians that any particular agent is the best choice. The lack of randomised designs also means that we do not know if survival benefits accrue from agents with modest objective radiological responses in the second-line setting. This also leads to a conundrum in the design of randomised second-line trials of novel agents: whilst patients commonly receive off-label second-line therapy, this is neither approved by regulatory authorities, nor standardised, making the choice of chemotherapy drug or placebo as a comparator arm open to debate. Single agent vinorelbine has a response rate (RR) of 16% and overall survival of 9.6 months at second-line (24). Combinations of gemcitabine and vinorelbine (RR 10%, OS 10.9 months, PFS 2.8 months) (25), gemcitabine and epirubicin (RR 13%, OS 9.3 months, PFS 6.3 months in a high dose group) (26), irinotecan, cisplatin, and mitomycin (RR 20%, OS 7.3 months, PFS 7.3 months) (27) and others have been reported. On balance, the tolerability and response rate of single agent vinorelbine has been favoured in practice and as a proposed control arm for a new generation of second-line trials. However retrospective data presented at the recent International Mesothelioma Interest Group meeting failed to confirm a meaningful rate of objective responses in routine clinical practice (Zauderer M, personal communication, September 2012). The second-line setting is still waiting for a new agent, which can demonstrate both responses and survival benefits in a randomised trial.

**Systemic therapy in the era of precision medicine**

The paradigm for drug development in the last century was empirical testing of new drugs in clinical trials, usually with *in vitro* or *in vivo* activity rather than specific molecular targets as the rationale for testing. In the
current century, a very different paradigm of therapeutic discovery has evolved, and is relying on genomic medicine to identify targets which can then be translated to the clinic. Mesothelioma, like other complex adult cancers, evolves through a multistep process of carcinogenesis involving genetic and epigenetic changes. Some of these genetic changes will be passenger mutations, which are present but do not confer a growth advantage. Others, however, are likely to be the important driver mutations which have been positively selected and are key to the pathogenesis of the tumor. Such mutations may be either ‘actionable’ or ‘druggable’. Actionable mutations are those which contribute to our understanding of an individual’s cancer in terms of prognosis or treatment selection. Druggable mutations are the holy grail of cancer therapeutic discovery, and are those for which drugs are available to specifically target the mutation. Unfortunately, no clearly actionable or druggable activating mutations or translocations have yet been identified in mesothelioma, and certainly none have been translated through to the clinic (28).

Nevertheless, over the past 10 years, a number of novel targeted agents which have shown activity in other diseases have been trialled empirically in mesothelioma, including epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and multi-targeted TKIs with effects on the vascular endothelial growth factor (VEGF) pathway amongst others. Single agent treatment with the EGFR TKIs gefitinib, and erlotinib, as well as the PDGFR β/C-Kit inhibitor imatinib showed no evidence of activity even as first-line treatment (29-31). Agents inhibiting the VEGF receptor, often in combination with other targets, have shown some evidence of activity in an unselected population, with response rates around 10% and PFS between 3 and 4 months (32-38) (Table 1). However, identifying predictors of benefit from these agents has proven difficult, with no predictive factors identified in extensive serum testing of the VEGF pathway in one recent study of sunitinib (33). The anti-VEGF antibody bevacizumab has been tested in a number of completed and ongoing trials, with the best evidence coming from a randomised phase II trial of bevacizumab in combination with cisplatin and pemetrexed chemotherapy which did not show improved PFS or OS, although subset analyses suggested that a low serum VEGF level may predict for improved outcomes on the combination (39). The combination of cisplatin and gemcitabine is no longer a standard first-line treatment in MPM, so the ongoing French MAPS study, which has to date randomised more than 300 of a planned 445 patients to either cisplatin and pemetrexed with placebo or bevacizumab, should clarify the use of this drug in combination with chemotherapy in around two years (Scherpereel, A. Personal communication, September 2012).

Important new targets in mesothelioma have been discussed in companion papers in this journal, with mesothelioma being molecularly characterised particularly by the loss of tumor suppressor genes, rather than gain of function mutations. The recent observation that BRCA associated protein 1 (BAP1) is inactivated in around a

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Setting</th>
<th>Number of patients</th>
<th>Partial response rate (%)</th>
<th>Survival (months)</th>
<th>Author, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vatalanib</td>
<td>VEGF</td>
<td>1st line</td>
<td>47</td>
<td>6</td>
<td>PFS 4.1; OS 10</td>
<td>Jahan 2012</td>
</tr>
<tr>
<td>Cedirinib</td>
<td>VEGF-2</td>
<td>2nd line</td>
<td>54</td>
<td>9</td>
<td>PFS 2.7; OS 9.8</td>
<td>Garland 2011</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>VEGFR, Flt-1, KDR, Flt-4, PDGFR</td>
<td>2nd line</td>
<td>53</td>
<td>12</td>
<td>PFS 3.5; OS: 6.1</td>
<td>Nowak 2012</td>
</tr>
<tr>
<td>Semaxanib</td>
<td>VEGFR, PDGFR</td>
<td>2nd line</td>
<td>9</td>
<td>11</td>
<td>PFS NA; OS 12.4</td>
<td>Kindler 2001</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>VEGFR, PDGFR, Raf-kinase</td>
<td>1st line</td>
<td>51</td>
<td>4</td>
<td>FFS* 3.7; OS 10.7</td>
<td>Dubey 2010</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>VEGFR, Flt-1, KDR, Flt-4, PDGFR</td>
<td>1st line</td>
<td>17</td>
<td>6</td>
<td>PFS 2.8; OS 8.3</td>
<td>Laurie 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd line</td>
<td>18</td>
<td>0</td>
<td>PFS 2.7; OS 6.7</td>
<td></td>
</tr>
<tr>
<td>Cediranib</td>
<td>VEGFR-2</td>
<td></td>
<td>50</td>
<td>10</td>
<td>PFS 1.8; OS 4.4</td>
<td>Campbell 2012</td>
</tr>
</tbody>
</table>

VEGF, vascular endothelial growth factor; PFS, progression free survival; OS, overall all survival; FFS, failure-free survival
quarter of mesothelioma tumors has raised the possibility that this subset may harbour a therapeutic target, although a number of different mutations were identified (40). BAP1 has a role in DNA repair, control of gene expression through histone modification, and enhancing progression through the G1-S checkpoint (41). The role of BAP1 in histone modification is of interest as it raises the theoretical possibility that histone deacetylase inhibitors (HDACi) may have activity in this disease, however the lack of clinical response in a recent large (n=660) randomised phase III trial of the HDACi vorinostat argues against this as an important therapeutic strategy in tumors with BAP1 loss, even in a subset of patients (42).

Another tumor suppressor gene which is frequently inactivated in this disease is neurofibromatosis type 2 (NF2), with NF2 loss occurring in around 40% of patients, mostly a different subset to those with BAP1 loss (40,43,44). NF2 encodes for the protein Merlin, which in turn interacts with more than 30 other intracellular proteins. Key pathways which may be open to manipulation are the Hpo (Hippo) pathway which is important in cell proliferation, the activation of mTORC1 by Merlin loss (45), the activation of the focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK) pathways, and the role of Merlin loss in removing inhibition of CRL4, a ubiquitin ligase, thus allowing broad dysregulation of transcription (46). Drug classes which have the potential for activity on the basis of these alterations include Mammalian Target of Rapamycin (mTOR) inhibitors, and the use of dual PI3K/mTOR inhibitors in view of the compensatory upregulation of PI3K seen with mTOR inhibition alone. A phase I trial of the PI3K/mTOR inhibitor GDC0980 demonstrated activity in a subset of patients with mesothelioma (47), with an expansion cohort with this disease now fully accrued and encouraging preliminary results reported at the recent International Mesothelioma Interest Group meeting (Kindler HL, personal communication, September 2012). The role of FAK inhibitors is similarly under study, due to the negative regulation of FAK by an intact Merlin protein via FAK phosphorylation.

The final pathway I will discuss in this incomplete overview is the hepatocyte growth factor (HGF)/c-Met pathway. C-Met receptor tyrosine kinase is overexpressed in the majority of mesothelioma and has been implicated in mesothelioma cell line growth, as well as successfully inhibited with both small molecular tyrosine kinase inhibitors, and siRNA, in in vitro experiments (48). Furthermore, combined inhibition of c-Met with EGFR may be better than either strategy alone in suppressing mesothelioma cell line growth (49). MET inhibitors are under development in a number of tumor types, and this pathway is relevant to test in the clinic in this disease.

**Conclusions**

These examples are not a comprehensive review of the numerous potential pathways which could be targeted in mesothelioma. However, equally important is the question of how best to bring agents to the clinic, and how to design clinical trials with the potential to show a signal of activity. In the maintenance and second-line setting, there is still a role for single agent testing. In the absence of routine maintenance treatment in mesothelioma, randomisation to a study drug versus placebo is appropriate, whilst a single-arm study would be difficult if not impossible to interpret. In the second-line or subsequent setting, either a single arm study with response as an endpoint, or preferably as a randomised phase II trial, will allow for evaluation of a signal for activity. There is no doubt that combination trials using cisplatin and pemetrexed with a novel agent need to include a randomisation arm to chemotherapy alone, or risk being uninterpretable; a single arm combination study is only appropriate if designed as a phase I trial. Key to the development of the next generation of agents in mesothelioma is the collection of robust correlare biospecimens, preferably as both tissue and serum or plasma. How else can we move the science of mesothelioma treatment forward rapidly? There is little doubt that advancing mesothelioma to the next stage of precision medicine will require an international collaborative effort and extensive high-quality well annotated tissue collections. The surgical fraternity can play a key role in development of mesothelioma drug therapeutics by collecting and clinically annotating appropriate tissue specimens from patients undergoing radical surgery, diagnostic procedures, or taking part in clinical trials, and collaborating with basic scientists and oncologists in this work.

**Acknowledgements**

The author thanks Tracy Hayward for assistance with submission.

**Disclosure:** Eli Lilly Australia: travel funding, advisory board; Roche Australia: research funding, advisory board; Boehringer Ingelheim Australia: travel funding, advisory board; Verastem: advisory board; Roche International:
advisory board.

References


Cite this article as: Nowak AK. Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg 2012;1(4):508-515. DOI: 10.3978/j.issn.2225-319X.2012.10.05